apomorphine has been researched along with pd 168,077 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
| Brioni, JD; Chang, R; Cowart, MD; Darbyshire, JF; Donnelly-Roberts, DL; El-Kouhen, OF; Gintant, G; Hakeem, AA; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martin, R; Martino, BR; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Nelson, SL; Patel, MV; Rohde, JJ; Stewart, AO; Sullivan, JP; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
| Argiolas, A; Mascia, MS; Melis, MR; Succu, S | 1 |
| Argiolas, A; Enguehard-Gueiffier, C; Gmeiner, P; Gueiffier, A; Hubner, H; Mascia, MS; Melis, MR; Melis, T; Sanna, F; Succu, S | 1 |
| Ikeda, K; Ikejiri, M; Kiyoshi, A; Kotani, M; Matsumoto, A; Matsumoto, K; Murai, T; Nakako, T; Ogi, Y | 1 |
5 other study(ies) available for apomorphine and pd 168,077
| Article | Year |
|---|---|
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug Evaluation, Preclinical; Erectile Dysfunction; Ferrets; Humans; Male; Models, Molecular; Molecular Structure; Oximes; Piperazines; Rats; Rats, Wistar; Receptors, Dopamine D4; Stereoisomerism; Structure-Activity Relationship | 2006 |
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Topics: Action Potentials; Administration, Oral; Animals; Benzamides; Biological Availability; Cell Line; Cyclic N-Oxides; Dogs; Erectile Dysfunction; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haplorhini; Humans; In Vitro Techniques; Male; Patch-Clamp Techniques; Purkinje Fibers; Rats; Receptors, Dopamine D4; Structure-Activity Relationship | 2006 |
PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzamides; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Male; NG-Nitroarginine Methyl Ester; Oxytocin; Paraventricular Hypothalamic Nucleus; Penile Erection; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D4 | 2005 |
PIP3EA and PD-168077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain.
Topics: Animals; Apomorphine; Behavior, Animal; Benzamides; Brain; Calcium Channel Blockers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Routes; Imidazoles; Male; Nitrates; Nitric Oxide; Nitrites; omega-Conotoxins; Paraventricular Hypothalamic Nucleus; Penile Erection; Piperazines; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D4 | 2006 |
The dopamine D1 receptor agonist SKF-82958 effectively increases eye blinking count in common marmosets.
Topics: Acetamides; Animals; Apomorphine; Benzamides; Benzazepines; Benzopyrans; Blinking; Callithrix; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Hypnotics and Sedatives; Male; Models, Animal; Oxazines; Piperazines; Pyridines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4 | 2016 |